Oxaceprol

Research use only, not for human use.

Oxaceprol is an established therapeutic agent for osteoarthritis.

Oxaceprol is an established therapeutic agent for osteoarthritis.(In Vitro):Oxaceprol, at 6 mg/kg/day for 7 days, significantly reduces both the surface area and wet weight of cotton pellet granulomas, being slightly less effective than indomethacin, 3 mg/kg.Oxaceprol (6–54 mg/kg/day) given therapeutically had no effect on the primary paw oedema response, but inhibits secondary lesions in the ears and tail.Oxaceprol does not inhibit the synthesis of prostaglandins in vitro, but markedly inhibits neutrophil infiltration into the joints of rats with adjuvant arthritis.

——

Oxaceprol, at 6 mg/kg/day for 7 days, significantly reduces both the surface area and wet weight of cotton pellet granulomas, being slightly less effective than indomethacin, 3 mg/kg.Oxaceprol (6–54 mg/kg/day) given therapeutically had no effect on the primary paw oedema response, but inhibits secondary lesions in the ears and tail.Oxaceprol does not inhibit the synthesis of prostaglandins in vitro, but markedly inhibits neutrophil infiltration into the joints of rats with adjuvant arthritis. Animal Model:Male Sprague-Dawley rats.Dosage:18, 50 or 150 mg/kg.Administration:Gavage daily for 15 days.Result:Produced comparable inhibition of hyperalgesia to that produced by indomethacin.

N-Acetyl-L-hydroxyproline

Others

Other Targets

Others

——

——

33996-33-7

173.17

C7H11NO4

>98% (HPLC)

DMSO:1 mg/mL (577.47 mM)

CC(=O)N1C[C@@H](C[C@H]1C(=O)O)O

(2S4R)-1-acetyl-4-hydroxypyrrolidine-2-carboxylic acid

(-20℃)

With Ice Pack

≥ 2 years